Gene therapy is an effective method for a wide range of genetic diseases, one of which is cystic fibrosis (CF) caused by gene mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The present study aimed to review the tools and studies focusing on the gene-editing of CF disease. Four main groups of endonuclease are currently used for genome editing, including meganucleases, zinc finger nucleases (ZFN), clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system, and transcription activator-like effector nucleases (TALEN). The use of these genome editing techniques has converted the promise of a therapeutic approach for this disease to an achievable goal. Nevertheless, these techniques have so far only been tested on stem cells and have not yet been used in clinical treatments, due to the multifaceted characteristics of cystic fibrosis. Certainly, further advances in these techniques with increased efficiency of DNA cleavage sites and strong optimization to reduce the defects of their carriers direct the future of genomic editing technology to in vivo treatment of cystic fibrosis